Revolutionizing Donor Heart Procurement: Innovations and Future Directions for Enhanced Transplantation Outcomes

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2024 Aug 28

PMID 39195143

Authors

Marc Leon

Affiliations

Soon will be listed here.

Abstract

Heart failure persists as a critical public health challenge, with heart transplantation esteemed as the optimal treatment for patients with end-stage heart failure. However, the limited availability of donor hearts presents a major obstacle to meeting patient needs. In recent years, the most groundbreaking progress in heart transplantation has been in donor heart procurement, significantly expanding the donor pool and enhancing clinical outcomes. This review comprehensively examines these advancements, including the resurgence of heart donation after circulatory death and innovative recovery and evaluation technologies such as normothermic machine perfusion and thoraco-abdominal normothermic regional perfusion. Additionally, novel preservation methods, including controlled hypothermic preservation and hypothermic oxygenated perfusion, are evaluated. The review also explores the use of extended-criteria donors, post-cardiopulmonary resuscitation donors, and high-risk donors, all contributing to increased donor availability without compromising outcomes. Future directions, such as xenotransplantation, biomarkers, and artificial intelligence in donor heart evaluation and procurement, are discussed. These innovations promise to address current limitations and optimize donor heart utilization, ultimately enhancing transplantation success. By identifying recent advancements and proposing future research directions, this review aims to provide insights into advancing heart transplantation and improving patient outcomes.

References

Critsinelis A, Patel S, Nordan T, Chen F, Couper G, Kawabori M . Trends in Outcomes of Heart Transplants Using Extended Criteria Donors: A United Network for Organ Sharing Database Analysis. Ann Thorac Surg. 2022; 115(6):1503-1509. DOI: 10.1016/j.athoracsur.2022.09.027. View

Weber D, Wang I, Gracon A, Hellman Y, Hormuth D, Wozniak T . Impact of donor age on survival after heart transplantation: an analysis of the United Network for Organ Sharing (UNOS) registry. J Card Surg. 2014; 29(5):723-8. DOI: 10.1111/jocs.12406. View

Sibona A, Khush K, Oyoyo U, Martens T, Hasaniya N, Razzouk A . Long-term transplant outcomes of donor hearts with left ventricular dysfunction. J Thorac Cardiovasc Surg. 2019; 157(5):1865-1875. DOI: 10.1016/j.jtcvs.2018.07.115. View

Urban M, Moody M, Lyden E, Kinen L, Castleberry A, Siddique A . Impact of donation after circulatory death heart transplantation on waitlist outcomes and transplantation activity. Clin Transplant. 2023; 37(5):e14942. DOI: 10.1111/ctr.14942. View

Brahmbhatt D, Blitzer D, Billia F, Copeland H . Acute complication posttransplant: primary allograft dysfunction. Curr Opin Organ Transplant. 2023; 28(5):376-383. DOI: 10.1097/MOT.0000000000001091. View

Smith D, Kon Z, Carillo J, Chen S, Gidea C, Piper G . Early experience with donation after circulatory death heart transplantation using normothermic regional perfusion in the United States. J Thorac Cardiovasc Surg. 2021; 164(2):557-568.e1. DOI: 10.1016/j.jtcvs.2021.07.059. View

Schroder J, Patel C, DeVore A, Casalinova S, Koomalsingh K, Shah A . Increasing Utilization of Extended Criteria Donor Hearts for Transplantation: The OCS Heart EXPAND Trial. JACC Heart Fail. 2024; 12(3):438-447. DOI: 10.1016/j.jchf.2023.11.015. View

Alamouti-Fard E, Garg P, Wadiwala I, Yazji J, Alomari M, Akram Hussain M . Normothermic Regional Perfusion is an Emerging Cost-Effective Alternative in Donation After Circulatory Death (DCD) in Heart Transplantation. Cureus. 2022; 14(6):e26437. PMC: 9246458. DOI: 10.7759/cureus.26437. View

Truby L, Kwee L, Bowles D, Casalinova S, Ilkayeva O, Muehlbauer M . Metabolomic profiling during ex situ normothermic perfusion before heart transplantation defines patterns of substrate utilization and correlates with markers of allograft injury. J Heart Lung Transplant. 2023; 43(5):716-726. DOI: 10.1016/j.healun.2023.12.002. View

10.

Colvin M, Smith J, Ahn Y, Handarova D, Martinez A, Lindblad K . OPTN/SRTR 2022 Annual Data Report: Heart. Am J Transplant. 2024; 24(2S1):S305-S393. DOI: 10.1016/j.ajt.2024.01.016. View

11.

Jaiswal A, Gadela N, Baran D, Balakumaran K, Scatola A, Radojevic J . Clinical outcomes of older adults listed for heart transplantation in the United States. J Am Geriatr Soc. 2021; 69(9):2507-2517. DOI: 10.1111/jgs.17271. View

12.

Joshi Y, Villanueva J, Gao L, Hwang B, Zhao C, Doyle A . Donation After Circulatory Death: A New Frontier. Curr Cardiol Rep. 2022; 24(12):1973-1981. PMC: 9747832. DOI: 10.1007/s11886-022-01798-y. View

13.

Copeland H, Awori Hayanga J, Neyrinck A, Macdonald P, Dellgren G, Bertolotti A . Donor heart and lung procurement: A consensus statement. J Heart Lung Transplant. 2020; 39(6):501-517. DOI: 10.1016/j.healun.2020.03.020. View

14.

Kulshrestha K, Greenberg J, Guzman-Gomez A, Kennedy 3rd J, Hossain M, Zhang Y . Up to an Hour of Donor Resuscitation Does Not Affect Pediatric Heart Transplantation Survival. Ann Thorac Surg. 2023; 117(3):611-618. PMC: 10693647. DOI: 10.1016/j.athoracsur.2023.04.043. View

15.

Gernhofer Y, Brambatti M, Greenberg B, Adler E, Aslam S, Pretorius V . The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate. J Heart Lung Transplant. 2019; 38(11):1178-1188. DOI: 10.1016/j.healun.2019.08.010. View

16.

Gaffey A, Doll S, Thomasson A, Venkataraman C, Chen C, Goldberg L . Transplantation of "high-risk" donor hearts: Implications for infection. J Thorac Cardiovasc Surg. 2016; 152(1):213-20. DOI: 10.1016/j.jtcvs.2015.12.062. View

17.

Wever Pinzon O, Stoddard G, Drakos S, Gilbert E, Nativi J, Budge D . Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant. 2011; 11(12):2755-61. PMC: 3602908. DOI: 10.1111/j.1600-6143.2011.03744.x. View

18.

Aslam S, Grossi P, Schlendorf K, Holm A, Woolley A, Blumberg E . Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant. 2020; 39(5):418-432. DOI: 10.1016/j.healun.2020.03.004. View

19.

Chen Q, Emerson D, Megna D, Osho A, Roach A, Chan J . Heart transplantation using donation after circulatory death in the United States. J Thorac Cardiovasc Surg. 2022; 165(5):1849-1860.e6. PMC: 11334953. DOI: 10.1016/j.jtcvs.2022.05.005. View

20.

Mohiuddin M, Singh A, Scobie L, Goerlich C, Grazioli A, Saharia K . Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet. 2023; 402(10399):397-410. PMC: 10552929. DOI: 10.1016/S0140-6736(23)00775-4. View